<p>中枢神经系统问题是全球第二大死因，世界卫生组织在 2022 年确定。欧洲生物科技新闻网站_Labiotech_去年报道称，造成这种情况的一个原因是由于中枢神经系统的复杂性，开发有效治疗这些疾病非常困难。此外，阻止有害物质进入我们大脑的血脑屏障也阻止许多药物对器官产生影响。</p>
<p>总的来说，找到安全、有效的药物，保险公司愿意支付的药物，并且比标准治疗更好的药物是一个极其漫长、艰难的过程，成功的可能性不大。考虑到开发神经治疗方面的增加困难，该领域的公司面临更加艰难的道路。</p>
<p>但对投资者的好消息是，如果公司确实开发出成功的神经药物，它们可能不会面临太多激烈的竞争。因此，以下是目前最好的三家神经科学生物技术股票。</p>
<h2>药明康德（VRTX）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Pavel Kapysh / Shutterstock.com</p>
<p>疼痛是一种神经现象。因此，<strong>药明康德</strong>（纳斯达克：<strong>VRTX</strong>）的中度至重度急性疼痛治疗药物，名为 suzetrigine，可以被视为一种神经药物。重要的是，suzetrigine 是一种非阿片类止痛药，使其比当今广泛使用的强力阿片类止痛药更不容易上瘾。</p>
<p>药明康德首席执行官 Reshma Kewalramani 解释说，公司的药物可以 “潜在地填补” 非常安全但相当弱的止痛药和容易上瘾的强力阿片类止痛药之间的差距。</p>
<p>在一项 3 期试验中，suzetrigine 成功地比安慰剂显著减轻了患者的手术和非手术疼痛。然而，它未能比阿片类药物羟考酮和对乙酰氨基酚的联合组合显著减轻患者的疼痛。</p>
<p>尽管如此，GlobalData 估计该药物将在 2030 年为药明康德带来 14 亿美元的收入。其他分析师认为，该治疗可能会带来数十亿美元的年度最高收入。</p>
<p>药明康德希望在上个季度结束前完成向 FDA 提交该药物作为 “中度至重度疼痛” 治疗的批准。</p>
<p>考虑到药明康德的非成瘾性止痛药的巨大潜力，我认为它是目前最好的生物技术股之一。</p>
<h2>英蓓（ESAIY）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：PopTika / Shutterstock.com</p>
<p>正如我在之前的专栏中所指出的，<strong>英蓓</strong>（OTCMKTS：<strong>ESAIY</strong>）的阿尔茨海默病药物 Leqembi 实际上改善了 60% 被认为处于早期疾病阶段的患者的认知能力。</p>
<p>与此同时，英蓓在五月份开始了该药物的生物制品许可申请（BLA）的滚动提交，这个版本与已经在使用的静脉注射版本不同，可以在医生办公室和家中给患者使用。此外，英蓓报道称，通过皮下机制，药物可以更快地被输送。鉴于这些因素，我相信在发布皮下版本后，对 Leqembi 的需求将大大增加。</p>
<p>到 2026 财年，英蓓预计该药物的销售额可以在截至 2027 年 3 月的财年达到近 20 亿美元，在截至 2033 年 3 月的财年达到 88 亿美元。</p>
<p>考虑到 Leqembi 的强效性和阿尔茨海默病治疗领域缺乏强有力的竞争，我相信该药物的收入可能大大超过这些目标。因此，我认为目前市值近 120 亿美元的公司被严重低估，是目前最好的生物技术股之一。</p>
<h2>神经一医疗（NMTC）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：everything possible / Shutterstock.com</p>
<p><strong>神经一医疗</strong>（纳斯达克：<strong>NMTC</strong>）利用薄膜电极技术开发产品。其产品被用于促进脑电图或 EEG，以确定大脑的电活动程度。神经一医疗的产品还被用于与脊髓刺激和脑刺激结合使用。</p>
<p>为神经一医疗及其产品提供重要验证的是，该公司与两家非常知名的医院，梅奥诊所和克利夫兰诊所合作。此外，该公司与一家大型医疗器械公司 <strong>Zimmer Biomet</strong>（纽约证券交易所：<strong>ZBH</strong>）合作。</p>
<p>令人印象深刻的是，神经一医疗是梅奥诊所持有股票的九家医疗保健公司之一。</p>
<p>此外，神经一医疗以惊人的速度增长，其产品收入从上个季度的 46.6 万美元增至 138 万美元，而去年同期为 46.6 万美元。</p>
<p>_在发布日期，Larry Ramer 持有 ESAIY 的多头头寸。本文中表达的观点属于作者个人，遵守 InvestorPlace.com 的发布准则。</p>
<p>_在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何头寸。</p>
<p>Larry Ramer 已经对美国股票进行了 15 年的研究和撰写文章。他曾在 The Fly 和以色列最大的商业报纸 Globes 工作。Larry 于 2015 年开始为 InvestorPlace 撰写专栏。他的一些非常成功的、违背潮流的选择包括 SMCI、INTC 和 MGM。您可以在 Stocktwits 上联系他，用户名为 @larryramer。</p>
<p>医疗保健、生物技术</p>

VERX

<p>中枢神经系统问题由于复杂性和血脑屏障的存在而难以治疗。然而，投资成功的神经药物可能会带来丰厚的利润。目前最值得购买的三家神经科学生物技术股票是 Vertex、Eisai 和 NeuroOne Medical。Vertex 拥有一种非成瘾性止痛药物 suzetrigine，具有强大的收入潜力。Eisai 的阿尔茨海默病药物 Leqembi 显示出有希望的结果，并且被低估。NeuroOne 开发用于大脑和脊髓刺激的产品，并与知名医院合作</p>

<p>Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it’s extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website <em>Labiotech</em> reported last year. Further, the blood-brain barrier that stops damaging substances from entering our brains also prevents many drugs from impacting the organ.</p>
<div class="lb-trans"><p>中枢神经系统问题是全球第二大死因，世界卫生组织在 2022 年确定。欧洲生物科技新闻网站_Labiotech_去年报道称，造成这种情况的一个原因是由于中枢神经系统的复杂性，开发有效治疗这些疾病非常困难。此外，阻止有害物质进入我们大脑的血脑屏障也阻止许多药物对器官产生影响。</p>
</div><p>In general, finding safe, effective drugs that insurers will pay for and that will be better than standard-of-care treatments is an extremely long, arduous process that’s unlikely to succeed. Given the enhanced difficulties involved with developing neurological treatments, companies in that space have an even harder road to traverse.</p>
<div class="lb-trans"><p>总的来说，找到安全、有效的药物，保险公司愿意支付的药物，并且比标准治疗更好的药物是一个极其漫长、艰难的过程，成功的可能性不大。考虑到开发神经治疗方面的增加困难，该领域的公司面临更加艰难的道路。</p>
</div><p>But the good news for investors is that, if companies do develop successful neurological drugs, they probably won’t face much tough competition. With that in mind, here are the three best neuroscience biotech stocks to buy now.</p>
<div class="lb-trans"><p>但对投资者的好消息是，如果公司确实开发出成功的神经药物，它们可能不会面临太多激烈的竞争。因此，以下是目前最好的三家神经科学生物技术股票。</p>
</div><h2>Vertex (VRTX)</h2>
<div class="lb-trans"><h2>药明康德（VRTX）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Pavel Kapysh / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：Pavel Kapysh / Shutterstock.com</p>
</div><p>Pain is a neurological phenomenon. Consequently, <strong>Vertex’s</strong> (NASDAQ:<strong>VRTX</strong>) moderate-to-severe acute pain treatment, called suzetrigine, can be viewed as a neurological drug. Importantly, suzetrigine is a non-opioid pain medication, making it much less addictive than the powerful opioid pain treatments widely used today.</p>
<div class="lb-trans"><p>疼痛是一种神经现象。因此，<strong>药明康德</strong>（纳斯达克：<strong>VRTX</strong>）的中度至重度急性疼痛治疗药物，名为 suzetrigine，可以被视为一种神经药物。重要的是，suzetrigine 是一种非阿片类止痛药，使其比当今广泛使用的强力阿片类止痛药更不容易上瘾。</p>
</div><p>Vertex CEO Reshma Kewalramani explained that his company’s drug can “potentially fill the gap” between very safe but fairly weak painkillers and strong, opioid painkillers that can easily become addictive.</p>
<div class="lb-trans"><p>药明康德首席执行官 Reshma Kewalramani 解释说，公司的药物可以 “潜在地填补” 非常安全但相当弱的止痛药和容易上瘾的强力阿片类止痛药之间的差距。</p>
</div><p>In a Phase-3 trial, suzetrigine successfully reduced patients’ surgical and non-surgical pain meaningfully more than a placebo. However, it failed to lessen patients’ pain significantly more than a combination of the opioid drug hydrocodone and acetaminophen.</p>
<div class="lb-trans"><p>在一项 3 期试验中，suzetrigine 成功地比安慰剂显著减轻了患者的手术和非手术疼痛。然而，它未能比阿片类药物羟考酮和对乙酰氨基酚的联合组合显著减轻患者的疼痛。</p>
</div><p>Nonetheless, GlobalData has estimated that the drug will generate a significant $1.4 billion of revenue for Vertex in 2030. Other analysts believe that the treatment could generate multi-billion dollar peak annual revenue.</p>
<div class="lb-trans"><p>尽管如此，GlobalData 估计该药物将在 2030 年为药明康德带来 14 亿美元的收入。其他分析师认为，该治疗可能会带来数十亿美元的年度最高收入。</p>
</div><p>Vertex hoped to finish submitting the drug to the FDA for its approval as a treatment for “moderate to severe pain” by the end of last quarter.</p>
<div class="lb-trans"><p>药明康德希望在上个季度结束前完成向 FDA 提交该药物作为 “中度至重度疼痛” 治疗的批准。</p>
</div><p>Given the strong potential of Vertex’s non-addictive painkiller, I view it as one of the best biotech stocks to buy at this point.</p>
<div class="lb-trans"><p>考虑到药明康德的非成瘾性止痛药的巨大潜力，我认为它是目前最好的生物技术股之一。</p>
</div><h2>Eisai (ESAIY)</h2>
<div class="lb-trans"><h2>英蓓（ESAIY）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: PopTika / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：PopTika / Shutterstock.com</p>
</div><p>As I’ve noted in previous columns, <strong>Eisai’s</strong> (OTCMKTS:<strong>ESAIY</strong>) Alzheimer’s drug, Leqembi, actually improved the cognition capabilities of 60% of patients thought to be in the early stages of the disease.</p>
<div class="lb-trans"><p>正如我在之前的专栏中所指出的，<strong>英蓓</strong>（OTCMKTS：<strong>ESAIY</strong>）的阿尔茨海默病药物 Leqembi 实际上改善了 60% 被认为处于早期疾病阶段的患者的认知能力。</p>
</div><p>Meanwhile, in May Eisai began a rolling submission of a Biologics License Application (BLA) for a subcutaneous version of the drug. If approved, this version, unlike the intravenous version that’s already being utilized, can be administered to patients in doctors’ offices and in homes. Additionally, the drug can be delivered more quickly via the subcutaneous mechanism than through IV, Eisai reported. Given these points, I believe that the demand for Leqembi will greatly increase after the subcutaenous version of it is released.</p>
<div class="lb-trans"><p>与此同时，英蓓在五月份开始了该药物的生物制品许可申请（BLA）的滚动提交，这个版本与已经在使用的静脉注射版本不同，可以在医生办公室和家中给患者使用。此外，英蓓报道称，通过皮下机制，药物可以更快地被输送。鉴于这些因素，我相信在发布皮下版本后，对 Leqembi 的需求将大大增加。</p>
</div><p>By fiscal 2026, Eisai predicts that the drug’s sales can reach almost $2 billion in its fiscal year that ends in March 2027 and $8.8 billion in its fiscal year that ends in March 2033.</p>
<div class="lb-trans"><p>到 2026 财年，英蓓预计该药物的销售额可以在截至 2027 年 3 月的财年达到近 20 亿美元，在截至 2033 年 3 月的财年达到 88 亿美元。</p>
</div><p>Given Leqembi’s strong efficacy and the lack of strong competition in the Alzheimer’s treatment space, I believe that the drug’s revenue can significantly exceed those targets. Consequently, I believe that the company, which currently has a market capitalization of almost $12 billion, is significantly undervalued and is one of the best biotech stocks to buy now.</p>
<div class="lb-trans"><p>考虑到 Leqembi 的强效性和阿尔茨海默病治疗领域缺乏强有力的竞争，我相信该药物的收入可能大大超过这些目标。因此，我认为目前市值近 120 亿美元的公司被严重低估，是目前最好的生物技术股之一。</p>
</div><h2>NeuroOne Medical ( <strong>NMTC</strong>)</h2>
<div class="lb-trans"><h2>神经一医疗（NMTC）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: everything possible / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：everything possible / Shutterstock.com</p>
</div><p><strong>NeuroOne</strong>(NASDAQ:<strong>NMTC</strong>) develops products using thin film electrode technology. Its offerings are being used to facilitate electroencephalograms or EEGs which determine the extent of electrical activity in the brain. NeuroOne’s products are also being used in conjunction with spinal cord stimulation and brain stimulation.</p>
<div class="lb-trans"><p><strong>神经一医疗</strong>（纳斯达克：<strong>NMTC</strong>）利用薄膜电极技术开发产品。其产品被用于促进脑电图或 EEG，以确定大脑的电活动程度。神经一医疗的产品还被用于与脊髓刺激和脑刺激结合使用。</p>
</div><p>Provoiding significant validation for NeurOne and its products, the firm partners with two very prestigious hospitals, Mayo Clinic and Cleveland Clinic. Additionally, the firm collaborates with a huge medical device company, <strong>Zimmer Biomet</strong> (NYSE:<strong>ZBH</strong>).</p>
<div class="lb-trans"><p>为神经一医疗及其产品提供重要验证的是，该公司与两家非常知名的医院，梅奥诊所和克利夫兰诊所合作。此外，该公司与一家大型医疗器械公司 <strong>Zimmer Biomet</strong>（纽约证券交易所：<strong>ZBH</strong>）合作。</p>
</div><p>Also impressively, NeuroOne is only nine healthcare firms whose stock is owned by the Mayo Clinic.</p>
<div class="lb-trans"><p>令人印象深刻的是，神经一医疗是梅奥诊所持有股票的九家医疗保健公司之一。</p>
</div><p>Moreover, NeuroOne is growing at an impressive rate as its product revenue jumped to $1.38 million last quarter compared to $466,000 during the same period a year earlier.</p>
<div class="lb-trans"><p>此外，神经一医疗以惊人的速度增长，其产品收入从上个季度的 46.6 万美元增至 138 万美元，而去年同期为 46.6 万美元。</p>
</div><p><em>On the date of publication, Larry Ramer held a long position in ESAIY. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines</em>.</p>
<div class="lb-trans"><p>_在发布日期，Larry Ramer 持有 ESAIY 的多头头寸。本文中表达的观点属于作者个人，遵守 InvestorPlace.com 的发布准则。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何头寸。</p>
</div><p>Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.</p>
<div class="lb-trans"><p>Larry Ramer 已经对美国股票进行了 15 年的研究和撰写文章。他曾在 The Fly 和以色列最大的商业报纸 Globes 工作。Larry 于 2015 年开始为 InvestorPlace 撰写专栏。他的一些非常成功的、违背潮流的选择包括 SMCI、INTC 和 MGM。您可以在 Stocktwits 上联系他，用户名为 @larryramer。</p>
</div><p>Healthcare, Biotech</p>
<div class="lb-trans"><p>医疗保健、生物技术</p>
</div>

当前值得购买的三只最佳神经科学生物技术股票